

Administered by: ___

COVID Immunization Consent Form

me (as it appea	irs on insurance card):		Da	ate of Birth:		Age: _	Sex:	Male / I
et Address: _		Room/U	nit:City:		State:		_ Zip Code:	:
l Address:		@	Phone:		SSN:			
e: 🗌 White	☐ Hispanic/Latino ☐	Black/African American	☐ Native American /Alaska	Native	Asian	lawaiian/Other Pacif	fic Islander [Other
DICAL HISTORY	: Complete the following qu	estions for the individua	al receiving the vaccine. If	ou answer "	YES", you may no	t be able to receiv	e the COVID-19	9 vaccine.
accine tempera	ner guidance is needed, refer Iture excursions, efficacy, saf Vaccination Providers about	fety, stability, dosage, vo	accine ingredients, mechai	nism of actio	n and administrat	tion.	*YES	NO
Are you feeling	-	0						
	received a dose of COVID-19 ccine product did you receiv		☐ Moderna ☐ Janssen (J	ohnson & Jo	hnson) 🗆 Anoth	er Product		
Have you receiv	ved a complete COVID-19 va	ccine series? (i.e., 1 dos	e Janssen or 2 doses of an					
	our vaccination record card of had an allergic reaction to:	or other documentation	1?					<u> </u>
•	de a severe allergic reaction	[e.g., anaphylaxis] that	required treatment with e	pinephrine o	r EpiPen® or that	caused you		
	ital. It would also include an	-		spiratory dis	tress, including w	heezing.)		
•	of a COVID-19 vaccine, includ e glycol (PEG), which is found	•	•	arations for (colonoscopy proc	aduras		
	, which is found in some vaco		<u> </u>		союнозсору ргос	euures		
A previous dose	e of COVID-19 vaccine	•	•					
•	had an allergic reaction to a	•	•	•				
	de a severe allergic reaction , ital. It would also include an				•	•		
Check all that a		unergie reaction that ec	auseu mves, sweming, or re	spiratory ais	tress, meraamig W	ricczing.,		
	etween ages 18 and 49 year							
	ween ages 12 and 29 years of							
•	of myocarditis or pericarditi Illergic reaction to something		or injectable therapy such:	as fond net	venom environm	nental or oralmedi	ication allergies	5
	and was treated with mono	_		35 100d, pct,	verioni, environi	icital of orallical	ication unergies	,
Diagnosed witl	h Multisystem Inflammatory	Syndrome (MIS-C or M	IS-A) after a COVID-19 infe	ection				
Have a bleedin	•							
Take a blood tl	hinner ned immune system (i.e., HI\	Vinfaction cancar) or to	ako immunosupprossivo d	ugs or thora	nios			
	of heparin-induced thrombo	·	ake illilliullosuppressive ui	ugs or thera	pies			
Am currently p	oregnant or breastfeeding	,, (,						
Have received								
History of Guil	lain-Barré Syndrome (GBS)							
tion 2: RELEAS	SE AND ASSIGNMENT:							
I have i	read or had explained to me	the Vaccine Recipient	Fact Sheet for COVID-19 v	accine risks	and benefits. To	read the Vaccine F	Recipient Emer	gency
Use Au	thorization Fact Sheet for ea	ach vaccine visit the we	bsite www.cvdvaccine.co	m: or you m	ay also visit the L	ocal Health Unit o	or private provi	der to
receive	a printed copy of the EUA F	Fact Sheet. To read the	Vaccine Recipient Emerge	ncy Use Aut	horization for Mo	oderna COVID-19 v	vaccine visit th	e
	e https://www.fda.gov/med		· 					
•	onsent to this COVID-19 pro	•		vaccinated v	with COVID-19 va	ccine.		
	y acknowledge that I have r	= =	-					
	stand that information abou	ut this COVID-19 vaccin	ation will be included in (SIMON) Sout	th Carolina Immu	nization Informat	ion System.	
My Insurance (
	rize the release of any medi							
	rize and request payment o that the authorization will o		=		zation			
_	that the photocopy of this f			the duthorn	zation.			
	<u>, </u>							
-	ow indicates I have read, u ipient Emergency Use of A			nd Assigni	ment of the CO	/ID-19 Immuniza	ation Consent	Form
nature of p	patient or guardian	X:			Dat	e:		
Below is fo	r pharmacy documentatio	on						
	er-Monovalent(12+)	Managala	ent Dose:	Route	Site Code	Lot Numbe	r:	
	, ,	☐ 1st Dose						
Ma.	derna Monovalent (12+) and Dose		□ IM				
	ionovalent XBB.1.5	- I I 3rd Dose			☐ RA			
· · /V	IUINUVALEINI ADD.1.3	1				Ī		

_____ Title: _____ Date Given:___